Bill113th Congress

H.R. 460

Patients' Access to Treatments Act of 2013

Ask AI
Introduced
Feb 4, 2013
Origin Chamber
House
Policy Area
Health
Latest Action
Feb 8, 2013

Sponsor

Rep. McKinley, David B. [R-WV-1]

Republican·WV-1
Bioguide ID: M001180
First Name: David
Middle Name: B.
Last Name: McKinley
By Request: N
142
Cosponsors
1
Committees
4
Actions
0
Amendments
0
Related Bills
3
Subjects
1
Summaries
3
Titles
1
Text Versions

Bill Details

Update Date
Nov 15, 2022
Origin Chamber
House
Bill Type
HR
Bill Number
460
Congress
113
Introduced Date
Feb 4, 2013
Policy Area
Health
Is Law
No
Feb 8, 2013Committee

Referred to the Subcommittee on Health.

Source: House committee actions

Feb 4, 2013IntroReferralH11100

Referred to the House Committee on Energy and Commerce.

Source: House floor actions

Feb 4, 2013IntroReferralIntro-H

Introduced in House

Source: Library of Congress

Feb 4, 2013IntroReferral1000

Introduced in House

Source: Library of Congress

Introduced in House· Feb 4, 20130

Patients' Access to Treatments Act of 2013 - Amends the Public Health Service Act to establish cost-sharing limits for health plans that cover prescription drugs and use a formulary or other tiered cost-sharing structure. Prohibits such a health plan from imposing cost-sharing requirements, including co-payment and co-insurance, applicable to prescription drugs in a specialty drug tier that exceed the dollar amount of cost-sharing requirements applicable to prescription drugs in a non-preferred brand drug tier. Applies the non-preferred brand drug tier for which beneficiary cost-sharing is lowest, if a formulary used by the health plan contains more than one non-preferred brand drug tier.

Defines: (1) "non-preferred brand drug tier" as a category of prescription drugs within a tier in a formulary for which beneficiary cost-sharing is greater than tiers for generic drugs or preferred brand drugs, and that are not included within a specialty drug tier; and (2) "specialty drug tier" as a category of prescription drugs within a tier in a formulary for which beneficiary cost-sharing is greater than tiers for generic drugs, preferred brand drugs, or non-preferred drugs in the plan's formulary.

Energy and Commerce Committee

House· Standing
Employee benefits and pensionsHealth care costs and insurancePrescription drugs

Introduced in House

Feb 4, 2013

Patients' Access to Treatments Act of 2013 — Informed